Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2107 • ACR Convergence 2022
Pregnancy Outcomes Among Women with Systemic Lupus Erythematosus (SLE): Impact of Preexisting Hypertension
azalfa Lateef¹, stephanie Bray², Dulaney Wilson², Jim Oates² and Diane Kamen², ¹MUSC, Columbia, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Advances in medicine for women with systemic lupus erythematosus (SLE) have led to improved pregnancy outcomes, but pregnancies are still high-risk and disparities remain.…
Abstract Number: PP10 • ACR Convergence 2022
How Advocating for My Autoimmune Disease Led Me to Desire to Pursue a Career in Rheumatology
Brooklyn Johnson¹ and Kathleen Collins², ¹Memphis, TN, ²LeBonheur Children's Hospital, Memphis, TN
Background/Purpose: The summer before my senior year, I developed a faint rash on my face and my arms. At a dermatology appointment, I pointed this…
Abstract Number: 0092 • ACR Convergence 2022
Characterizing Levels of Specialist Care Received by Patients with Systemic Lupus Erythematosus: Clinical Characteristics, Emergency Care, Hospitalization, and Costs Among Commercially-insured Adults in the United States
Sandra Sze-jung Wu¹, Allison Perry², Helen Varker³, Christine Dube¹ and Gary Bryant⁴, ¹AstraZeneca, Wilmington, DE, ²IBM Watson Health, Cambridge, MA, ³Merative, Cambridge, MA, ⁴AstraZeneca, New Castle, DE
Background/Purpose: Heterogeneous SLE manifestations can delay referral and diagnosis by a rheumatologist (rheum) in as many as 75% of patients (pts) with SLE.1 After diagnosis,…
Abstract Number: 0318 • ACR Convergence 2022
Development and Validation of Algorithms to Identify Cutaneous Lupus Patients Using Diagnostic Codes and Prescription Data
Lisa Guo¹, Jordan Said², Vinod Nambudiri³ and Joseph Merola³, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Harvard Medical School, Brigham and Women's Hospital, Boston, MA
Background/Purpose: There is a paucity of epidemiological studies of cutaneous lupus erythematosus (CLE), which may be due in part to the lack of well-validated methods…
Abstract Number: 0336 • ACR Convergence 2022
Machine Learning Approach for the Prediction of Lupus Nephritis Renal Flares Using Polygenic Risk Score and Electronic Health Record
Yi-Ming Chen¹, Tzu-Hung Hsiao¹, Seng-Cho Chou² and Chi-Wei Chung², ¹Taichung Veterans General Hospital, Taichung, Taiwan, ²Department of Information Management, National Taiwan University, Taipei, Taiwan
Background/Purpose: Lupus nephritis (LN) flares are associated with risks of renal failure and mortality in patients with systemic lupus erythematous (SLE). It is critical to…
Abstract Number: 0353 • ACR Convergence 2022
Steroid-Induced Diabetes in Lupus Nephritis Patients: Classic Risk Factors or a Different Type of Diabetes?
Cristian Alejandro Dimas Ramírez¹, André Fortanell-Meza¹, Diego San Agustin-Morales¹, Eduardo Brenner Muslera², Juan Mejia-Vilet³, Paloma Almeda-Valdes⁴, Paola Vázquez Cárdenas⁵, F. Javier Merayo-Chalico⁶ and Ana Barrera-Vargas¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ²School of Medicine of Universidad Panamericana, Ciudad de México, Mexico, ³National Autonomous University of Mexico, Ciudad de México, Mexico, ⁴Department of Endocrinology and Metabolism, and the Research Unit of Metabolic Diseases. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ⁵Hospital General Dr. Manuel Gea González, Ciudad de México, Mexico, ⁶Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirn", Ciudad de México, Mexico
Background/Purpose: Glucocorticoids are frequently employed in the treatment of systemic lupus erythematosus (SLE) patients and play a critical role in the induction therapy of lupus…
Abstract Number: 0537 • ACR Convergence 2022
Neutrophil Extracellular Traps as a Biomarker to Predict Outcomes in Lupus Nephritis
Laura Patricia Whittall Garcia¹, Farnoosh Naderinavi¹, Zahi Touma², Dafna Gladman³, Murray Urowitz⁴, Anna Konvalinka¹ and Joan Wither⁵, ¹University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Neutrophil Extracellular Traps (NETs) have been implicated in Lupus Nephritis (LN) pathogenesis. SLE neutrophils release High Mobility Group Box-1 (HMGB1) protein, in turn, HMGB1…
Abstract Number: 0640 • ACR Convergence 2022
Immune Cell Heterogeneity in Lupus Nephritis Kidneys and Its Relation to Histopathological Features
Arnon Arazi¹, Joseph Mears², Thomas Eisenhaure³, Qian Xiao⁴, Paul Hoover⁴, Deepak Rao⁴, Celine Berthier⁵, Andrea Fava⁶, Siddarth Gurajala⁴, Michael Peters³, Tony Jones³, William Apruzzese⁴, Jennifer Barnas⁷, Richard Furie⁸, Anne Davidson⁹, David Hildeman¹⁰, Judith James¹¹, Joel Guthridge¹¹, Maria Dall'Era¹², David Wofsy¹³, Peter Izmirly¹⁴, H Michael Belmont¹⁵, Robert Clancy¹⁴, Diane Kamen¹⁶, Chaim Putterman¹⁷, Thomas Tuschl¹⁸, Maureen McMahon¹⁹, Jennifer Grossman¹⁹, Kenneth Kalunian²⁰, Michael Weisman²¹, Matthias Kretzler⁵, Michael Brenner²², Jennifer Anolik²³, Michelle Petri²⁴, Jill Buyon¹⁴, Soumya Raychaudhuri⁴, Nir Hacohen³, Betty Diamond⁹ and the Accelerating Medicines Partnership RA/SLE Network³, ¹Feinstein Institutes for Medical Research, Melrose, MA, ²Michigan University, Ann Arbor, MI, ³Broad Institute, Cambridge, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵University of Michigan, Ann Arbor, MI, ⁶Johns Hopkins University, Baltimore, MD, ⁷University of Rochester, Rochester, NY, ⁸Northwell Health, Great Neck, NY, ⁹Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁰Cincinnati Children's Hospital, Cincinnati, OH, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²University of California, Division of Rheumatology, San Francisco, CA, ¹³University of California San Francisco, SF, CA, ¹⁴NYU Grossman School of Medicine, New York, NY, ¹⁵NYU School of Medicine, New York, NY, ¹⁶Medical University of South Carolina, Charleston, SC, ¹⁷Albert Einstein College of Medicine, Bronx, NY, ¹⁸Rockefeller University, New York, NY, ¹⁹University of California Los Angeles, Los Angeles, CA, ²⁰University of California San Diego, La Jolla, CA, ²¹Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ²²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²³University of Rochester Medical Center, Rochester, NY, ²⁴Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) is characterized by considerable variability in its clinical manifestations and histopathological findings. Understanding the cellular and molecular mechanisms underlying this heterogeneity…
Abstract Number: 0660 • ACR Convergence 2022
Serum Proteins and Metabolites Differ in SLE Patients with Coronary Microvascular Dysfunction (CMD) as Determined by Cardiac MRI Compared to SLE Patients Without CMD – a Pilot Study
Audrey Hagiwara¹, Moumita Bose¹, Aleksandr Stotland¹, Aleksandra Binek¹, Koen Raedschelders¹, Janet Wei¹, C. Noel Bairey Merz¹, Sarah Parker¹, Jennifer Van Eyk¹, Daniel Wallace¹, Mariko Ishimori² and Caroline Jefferies¹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Cedars-Sinai Health System, Los Angeles, CA
Background/Purpose: Cardiovascular disease (CVD) is a significant cause of mortality in patients with SLE. While obstructive coronary artery disease (CAD) is a leading cause of…
Abstract Number: 0800 • ACR Convergence 2022
Antibody Response to Shingrix Vaccination in Patients with Rheumatoid Arthritis, Seronegative Spondyloarthropathy and Systemic Lupus Erythematosus on Immunosuppressive Medications
Alina Kifayat¹, amy Wasserman², Kirk Sperber¹, Deana Nes³, Paul Arnaboldi⁴ and Julia Ash⁵, ¹New York Medical College at Westchester Medical Center, Valhalla, NY, ²New York Medical College at Westchester Medical Center, Armonk, NY, ³Bergen Medical Associates, Ridgewood, NJ, ⁴New York Medical College, Valhalla, NY, ⁵New York Medical College at Westchester Medical Center, Dobbs Ferry, NY
Background/Purpose: In patients with rheumatic diseases herpes zoster (HZ) has been identified as one of the most common infections associated with immunosuppression. Shingrix is a…
Abstract Number: 0964 • ACR Convergence 2022
High Rates of Fetal Growth Restriction in Systemic Lupus Erythematosus Pregnancies
Raeann Whitney, Sarah Green, Alex Camai, Ashley Suh, Katherine Walker, Wheless Lee and April Barnado, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Fetal growth restriction (FGR) and small for gestational age (SGA) are associated with increased perinatal morbidity and mortality. While Systemic lupus erythematosus (SLE) increases…
Abstract Number: 0985 • ACR Convergence 2022
S100 Serum Protein Expression Is a Useful Indicator of HCQ Treatment Efficacy in SLE
Risa Wakiya¹, Hiromi Shimada¹, Kiyo Ueeda², Shusaku nakashima¹, Mikiya Kato¹, Taichi Miyagi¹, Yusuke Ushio³, Koichi Sugihara¹, Rina Mino³, mao mizusaki⁴, Kanako Chujo⁵, Tomohiro Kameda¹ and Hiroaki Dobashi⁶, ¹Kagawa University, Miki-cho, Kita-gun, Japan, ²Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ³Kagawa university, Kagawa, Japan, ⁴Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Miki-cho, Kita-gun, Japan, ⁵Kagawa University, Miki, Kita District, Kagawa, Japan, ⁶Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan
Background/Purpose: It is known that type 1 IFN and proinflammatory cytokines are associated with the pathogenesis of systemic lupus erythematosus (SLE). Recently, the S100 protein,…
Abstract Number: 1002 • ACR Convergence 2022
Investigation of Pharmacodynamic Biomarkers in a Phase 2b Study in Patients with Moderate to Severe SLE Treated with the S1P1 Receptor Modulator Cenerimod
Daniel Strasser¹, clélia Cahuzac², peter Cornelisse², Ouali Berkani², Peter Groenen² and Mark Murphy², ¹Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland, ²Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland
Background/Purpose: Sphingosine-1-phosphate (S1P) regulates lymphocyte egress from lymphoid organs into circulation. In a SLE proof-of-concept study, cenerimod—a potent, selective S1P1 receptor modulator—reduced circulating antibody-secreting cells…
Abstract Number: 1198 • ACR Convergence 2022
Validation of Remote Physical Performance and Cognitive Functioning Measures Among Individuals with Systemic Lupus Erythematosus
Courtney Hoge¹, C. Barrett Bowling², Charmayne Dunlop-Thomas¹, Bradley Pearce¹, S. Sam Lim¹, Cristina Drenkard¹ and Laura Plantinga¹, ¹Emory University, Atlanta, GA, ²Duke University, Durham, NC
Background/Purpose: The disruption of the COVID-19 pandemic presented an opportunity for researchers to develop and administer remote versions of measures for ongoing studies. In an…
Abstract Number: 1371 • ACR Convergence 2022
Juvenile Onset SLE in India-Data from a Multi-institutional Inception (INSPIRE) Cohort of Systemic Lupus Erythematosus
Amita Aggarwal¹, Liza Rajasekhar², Parasar Ghosh³, Ashish J Mathew⁴, Chengappa Kavadichanda⁵, Vineetha Shobha⁶, Ranjan Gupta⁷, Saumya Ranjan Tripathy⁸, Manish Rathi⁹, Avinash Jain¹⁰ and Able Lawrence¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Nizam's Institute of Medical Sciences, Madhapur, India, ³Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁴Rigshospitalet, Copenhagen, Denmark, ⁵JIPMER, Pondicherry, Puducherry, India, ⁶St. John’s Medical College Hospital, Bangalore, India, ⁷All India Institute of Medical Sciences, New Delhi, India, ⁸SCB medical college, Cuttack, India, ⁹PGIMER Chandigarh, Chandigarh, India, ¹⁰SMS Medical College, Lucknow, India
Background/Purpose: Most Lupus cohorts across the globe have poor representation of patients from South Asia who are ethnically different. We explored the clinical features and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].